ACEi, ARB Use Linked to Lower Risk for Kidney Failure With Replacement Therapy
By Elana Gotkine HealthDay Reporter
MONDAY, July 8, 2024 -- For individuals with advanced chronic kidney disease (CKD), angiotensin-converting enzyme inhibitor (ACEi) or angiotensin-receptor blocker (ARB) treatment is associated with a reduced risk for kidney failure with replacement therapy (KFRT) but not death, according to a study published online July 2 in the Annals of Internal Medicine.
Elaine Ku, M.D., from the University of California in San Francisco, and colleagues examined the association of ACEi or ARB treatment initiation with rates of KFRT and death using data from completed randomized controlled trials from 1946 through Dec. 31, 2023.
Data were included for 1,739 participants from 18 trials, and of these patients, 35.9 and 7.6 percent developed KFRT and died, respectively, during a median follow-up of 34 months. The researchers found that the risk for KFRT was lower with ACEi or ARB treatment initiation (adjusted hazard ratio, 0.66; 95 percent confidence interval, 0.55 to 0.79), but the risk for death was not significantly lower (adjusted hazard ratio, 0.86; 95 percent confidence interval, 0.58 to 1.28). No significant interactions were seen between ACEi or ARB treatment and age, estimated glomerular filtration rate, albuminuria, or diabetes.
"Initiation of ACEi or ARB therapy protects against KFRT, but not against death, in people with advanced CKD," the authors write. "Even in an era where other agents, such as sodium-glucose cotransporter-2 inhibitors, are available, significant benefit can be derived from the initiation of ACEi or ARB treatment in patients with low glomerular filtration rate."
Several authors disclosed ties to the pharmaceutical industry.
Abstract/Full Text (subscription or payment may be required)
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
Source: HealthDay
Posted : 2024-07-09 03:15
Read more
- Quitting Smoking After Cancer Diagnosis Boosts Survival by Up to 26%
- Election Fears Are Keeping Americans Awake at Night, Survey Shows
- Even 'Weekend Warrior' Exercise Can Keep Your Brain Healthy
- Clinicians Often Fail to Rescue Women With Complications After High-Risk Surgery
- Nektar Announces Publication in Nature Communications of Results from Phase 1b Studies of Rezpegaldesleukin in Two Inflammatory Skin Diseases
- AI Might Help Pick Up Heart Trouble in Dogs
Disclaimer
Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.
The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.
Popular Keywords
- metformin obat apa
- alahan panjang
- glimepiride obat apa
- takikardia adalah
- erau ernie
- pradiabetes
- besar88
- atrofi adalah
- kutu anjing
- trakeostomi
- mayzent pi
- enbrel auto injector not working
- enbrel interactions
- lenvima life expectancy
- leqvio pi
- what is lenvima
- lenvima pi
- empagliflozin-linagliptin
- encourage foundation for enbrel
- qulipta drug interactions